Navigation Links
Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
Date:4/6/2009

CALGARY, April 6 /PRNewswire/ - Orcrist Bio Inc. (ORC) a biotechnology company developing stem cell-mobilizing pharmaceuticals, announced today the approval of its Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers, by the European Competent Authority in Seville, Spain. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protected formulation of hyaluronan. The planned study will be conducted by InPEC BV (Breda, Netherlands) at their clinical trial site in Malaga, Spain.

"The approval of our Phase I clinical trial by the European authorities is another significant accomplishment for Orcrist," said Dr. Brett Schonekess, President and CEO of Orcrist. "With this approval we are now positioned to move forward with InPEC as our clinical partner and further develop HYC750 with the goal of confirming its safety profile, and to provide for a clear illustration of its stem cell mobilization properties. Ultimately, this is a key step to further advance the development of our product as a treatment for chemotherapy-related blood cell depletion."

About Orcrist Bio Inc.

Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists. ORC's lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related blood cell depletion. Orcrist is actively looking to add to its pipeline exploring the innate properties of HYC750 and its effects on stem cells, as well as through in-licensing opportunities of other products with clear market potential. ORC is located in Calgary, Alberta. The company is financed by its founders and by private investors.

About InPEC BV

InPEC BV is a clinical CRO that focuses on the execution of Phase I and IIa clinical trials. Its professional and experienced team, and state of the art facilities, embedded within the care of a private hospital with an ICU unit on the same floor, guarantee maximum safety for the full range of clinical pharmacology studies. Electronic data processing procedures are in place to enable high-quality and efficient data processing on-site. InPEC's head office is located in the Netherlands. Clinical facilities are located in Malaga, Spain.


'/>"/>
SOURCE Orcrist Bio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
2. CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture
3. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
4. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
5. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
6. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
7. PAREXEL Receives BioSingapore Award for Best Performing CRO
8. Isolagen, Inc. Receives Notification Letter from Amex
9. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
10. Dow AgroSciences Receives Approval for New Technology to Control Cotton Pests in Brazil
11. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies ... options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, launched ... space at 3624 Market Street. , Vironika is developing a treatment for a ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
(Date:1/19/2017)... Basel, Switzerland (PRWEB) , ... ... ... leading provider of advanced software solutions for pharmaceutical research and development (R&D), ... project-based expertise in omic data analysis and interpretation for the rapidly evolving ...
(Date:1/19/2017)... ... 2017 , ... The American Medical Informatics Association (AMIA) today ... Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should be ... recommended that NIH earmark funding for researchers to produce and execute data sharing ...
Breaking Biology Technology:
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):